Nuvectis Pharma (NVCT) Payables (2021 - 2026)

Nuvectis Pharma has reported Payables for 6 years, with the latest figure at $4.7 million in Q1 2026.

• Quarterly Payables rose 56.92% year-over-year to $4.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.7 million (up 56.92% YoY) and the FY2025 annual result came in at $6.3 million, up 151.16% from the prior year.
• Payables retreated to $4.7 million in Q1 2026 per NVCT's latest filing, from $6.3 million in the prior quarter.
• Over five years, Payables peaked at $6.4 million in Q3 2025 and troughed at $1.3 million in Q1 2022.
• A 5-year average of $3.0 million and a median of $2.5 million in 2024 frame the typical range for Payables.
• The sharpest annual moves came in 2024 and 2025: Payables tumbled 35.25% in 2024, then surged 184.79% in 2025.
• Over 5 years, Payables stood at $2.9 million in 2022, then slipped by 4.78% to $2.8 million in 2023, then declined by 9.85% to $2.5 million in 2024, then jumped by 151.16% to $6.3 million in 2025, then decreased by 25.17% to $4.7 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $4.7 million, $6.3 million, and $6.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.